Company Overview of GlobeImmune Inc.
GlobeImmune Inc. operates as a biopharmaceutical company. The company develops and manufactures Tarmogens, a molecular immunotherapy vaccine for the treatment of cancer and infectious diseases. Its products include GI-4000 for pancreas, non-small cell lung, colorectal, endometrial, and ovarian cancers, as well as melanoma and multiple myeloma; GI-6207 for the treatment of human epithelial cancers, including non-small cell lung cancer, colorectal, pancreas, breast, gastric, and medullary thyroid cancers; GI-6301, a Tarmogen used for the treatment of lung, breast, colon, bladder, kidney, ovary, uterus, and prostate cancers; and GS-4774 a therapeutic vaccine for chronic HBV infection. GlobeImmu...
1450 Infinite Drive
Louisville, CO 80027
Founded in 1995
Key Executives for GlobeImmune Inc.
Chief Executive Officer
Total Annual Compensation: $388.1K
Principal Financial & Accounting Officer
Total Annual Compensation: $191.5K
Vice President of Corporate Development
Total Annual Compensation: $188.8K
Compensation as of Fiscal Year 2013.
GlobeImmune Inc. Key Developments
GlobeImmune Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 09:30 AM
Aug 30 14
GlobeImmune Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 09:30 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Timothy C. Rodell, Chief Executive Officer, President and Director.
GlobeImmune Inc. Announces Financial Results for the Second Quarter and Six Months Ended June 30, 2014
Aug 15 14
GlobeImmune Inc. announced financial results for the second quarter and six months ended June 30, 2014. The net loss for the second quarter was $5.7 million, bringing the net loss for the year to $8.2 million.
For the six months ended June 30, 2014, the company reported a net loss of $8.2 million compared to a net loss of $0.5 million for the comparable period in the six months ended June 30, 2013.
GlobeImmune, Inc.(NasdaqCM:GBIM) added to NASDAQ Composite Index
Jul 3 14
GlobeImmune, Inc. will be added to the NASDAQ Composite Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 31, 2014
November 12, 2013